Thrombolytic drugs are mainly drugs that dissolve blood clots formed in blood vessels, because various factors lead to the formation of fibrin monomers in the inner wall of blood vessels, thus forming blood clots, which will block blood vessels and cause a series of clinical symptoms, and the drugs that need to dissolve blood clots are referred to as thrombolytic drugs. There are two kinds of thrombolytic drugs most commonly used: 1) Urokinase, which is the most commonly used drug in clinical practice, has a long time window for thrombolytic treatment, requiring it to be used within 6 hours of the onset of the disease; 2) recombinant tissue-type fibrinogen activator, also known as rtPA, has a very strict time limit for thrombolysis, and the total amount of the drug should be controlled very strictly and used within 3-4.5 hours of the onset of the disease. Thrombolysis must pay attention to the complications of thrombolysis to avoid visceral and intracranial hemorrhage, resulting in life-threatening.